Study centre in Würzburg

In the European Network for the Study of Adrenal Tumors (ENS@T), specialist centers across Europe work together to investigate benign and malignant adrenal tumors. By comparing clinical data and examining tumor material or blood samples, differences in the development of these tumors and their clinical characteristics can be investigated, thereby indirectly improving the care of those affected.

Conn's syndrome (primary hyperaldosteronism) describes a disease of the adrenal glands in which there is an increased production of the endogenous hormone aldosterone. To date, Conn syndrome has not been sufficiently researched and the care of patients worldwide is unsatisfactory. For this reason, the German Conn Registry was founded to better investigate the disease and improve treatment for patients. By participating in the "German Conn Register", you are actively supporting research into Conn syndrome and helping to improve treatment of the disease in the long term.

Cushing's syndrome is a very rare hormonal disorder. It is caused by an overproduction of the body's own hormone cortisol (hypercortisolism), which is triggered by a tumor. To date, Cushing's syndrome has not been sufficiently researched and the care of patients worldwide is unsatisfactory. For this reason, the German Cushing's Disease Registry was founded in 2012 to better investigate the disease and improve treatment for patients. By participating in the "German Cushing's Registry", you are actively supporting research into Cushing's syndrome and helping to improve treatment of the disease in the long term.

Multicenter Pheochromocytoma and Paraganglioma Evaluation for Follow-up Screening, Genetics Sub-Typing, Therapy and Outcome

PROSPHEO is an international multicenter registry study on pheochromocytomas and paragangliomas (PPGLs). The main question of the study is whether improved follow-up (pro-active, structured and periodic disease screening and management) leads to less morbidity and mortality and thus to an improved long-term outcome compared to standard follow-up. In the study, patients are randomly assigned to an intervention (improved follow-up vs. standard follow-up).

All patients who suffer from PPGL, have been treated for PPGL in the past or have a high probability of developing the disease for family/genetic reasons can take part in the study. The study is set to run for a total of 12 years. The first patients were included from November 2017.

The study centers in Germany are currently the University Hospital Carl-Gustav-Carus at TU Dresden (Christina Pamporaki), the Medical Clinic City Center of LMU Munich (Martin Reincke) and the University Hospital of Julius-Maximilians-Universität Würzburg (Martin Fassnacht). Outside of Germany, the Radboud University Nijmegen (Henri Timmers) in the Netherlands and the University Hospital Zurich (Felix Beuschlein) in Switzerland are involved in the study. (Source:  German Endocrine Society/Deutsche Gesellschaft für Endokrinologie)

(A multicentre PROspective study on the diagnostic value of Steroid profiling in primary ALDOsteronism)

PROSALDO (A multicentre PROspective study on the diagnostic value of Steroid profiling in primary ALDOsteronism) is a multicenter prospective study on the diagnostic value of steroid profiling in primary hyperaldosteronism. The main objective of the study is to determine predictive values of peripheral venous plasma steroids for the diagnosis and subtyping of primary aldosteronism. All persons suffering from hypertension and with an initial suspicion of primary hyperaldosteronism can be included in the study. The study is designed for a total period of 3 years. The first patients were included from March 2019.

Study centers in Germany are currently the University Hospital Carl Gustav Carus at the TU Dresden (study director: Graeme Eisenhofer) as well as the Medical Clinic Innenstadt of the LMU Munich (Martin Reincke) and the University Hospital of the Julius-Maximilians-University Würzburg (Stephanie Hahner). Outside of Germany, study centers in the Netherlands are Radboud University Nijmegen (Jaap Deinum), in Switzerland the University Hospital Zurich (Felix Beuschlein), in Poland the Institute of Cardiology in Warsaw (Aleksander Prejbisz) and in Italy the University of Turin (Paolo Mulatero) are involved in the study. (Source: German Endocrine Society/Deutsche Gesellschaft für Endokrinologie)

Neuroendocrine tumors of the gastro-entero-pancreatic system as well as pituitary and hypothalamic masses and tumors of the adrenal glands are very rare diseases that originate in the digestive system, the pituitary gland or the adrenal glands and can either directly cause the release of hormones or influence the release of hormones. The effects and therefore also the clinical treatment of the diseases mentioned can vary greatly, depending on whether the tumor growth and / or the excess hormones are in the foreground and where in the body the tumor or the disease is located. The Network of Excellence for Neuroendocrine Tumors and Pituitary and Adrenal Diseases aims to systematically investigate the complaints, symptoms, treatment response, sequelae, prognosis and mortality of all these different neuroendocrine tumors.

Retro- and prospective non-interventional observational study. Under the direction of the Endocrinology Department of the University Hospital of Würzburg, the Adrenal Insufficiency Registry centrally collects biodata and materials from patients with chronic adrenal insufficiency. Open recruitment. (Source: Universitätsklinikum Würzburg)

The non-interventional observational study is a European multicenter study in several countries investigating the safety of patients with chronic adrenal insufficiency who are under long-term treatment with the active substance Plenadren or are being substituted with other glucocorticoids. Recruitment open. (Source: Universitätsklinikum Würzburg)